EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression – A first-in-kind open-label pilot study

Sara Ellis, Catherine Bostian, Wendy Feng, Eileen Fischer, Garrett Schwartz, Katherine Eisen, Melanie Lean, Elizabeth Conlan, Michael Ostacher, Scott Aaronson, Trisha Suppes

Journal of Affective Disorders · 2025

DOI: 10.1016/j.jad.2024.09.133 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Affective Disorders, 2025. Verfasst von Sara Ellis und 10 weiteren Autor:innen. Beteiligte Einrichtung: VA Palo Alto Health Care System, Palo Alto, CA, USA; Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo A…. Hauptthemen laut MEDLINE: Depressive Disorder, Treatment-Resistant, Psilocybin, Veterans. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Compass Therapeutics LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The enduring and severe depression often suffered by Veterans causes immense suffering and is associated with high rates of suicide and disability. This is the first study to evaluate the efficacy and safety of psilocybin in Veterans with severe treatment-resistant depression (TRD). METHODS: 15 Veterans with severe TRD (major depressive episode failing to respond to ≥5 treatments, or lasting >2 years) received 25 mg of psilocybin. Primary outcome was change in Montgomery-Åsberg Depression Rating scale (MADRS) at 3 weeks posttreatment. Response was defined s ≥ 50 % reduction in MADRS, and remission as ≤10 MADRS score. Psychedelic experience was assessed using the Five-Dimensional Altered States of Consciousness scale (5D-ASC). Safety measures included assessment of suicidality and adverse events. Participants on antidepressants were tapered to avoid drug interactions. RESULTS: Of 15 participants, 60 % met response and 53 % met remission criteria at Week 3. At 12 weeks, 47 % maintained response, and 40 % remission. Co-morbid PTSD did not significantly influence study outcomes. The psychedelic experience reported in 5D-ASC did not correlate with response. Participants judged to need antidepressants were restarted and considered non-responders from that timepoint (n = 4). No unexpected adverse events occurred. LIMITATIONS: Limitations include the small sample size, and the uncontrolled and unblinded nature of the study. CONCLUSIONS: In this first study on psilocybin for Veterans with severe TRD, a surprising response and remission was seen. Many Veterans had PTSD though no moderating impact of response was observed. The degree of psychedelic experience did not correlate with depression changes. Further study is warranted. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04433858.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Depressive Disorder, Treatment-ResistantPsilocybinVeteransAdultFemaleHumansMaleMiddle AgedAntidepressive AgentsMajor Depressive DisorderHallucinogensPilot ProjectsPsychiatric Status Rating ScalesTreatment OutcomeUnited States

Stichwörter der Autor:innen

DepressionPsilocybinPsychedelicsTreatment-resistant depressionVeterans

Substanzen

Antidepressive AgentsHallucinogensPsilocybin

Autor:innen und Institutionen

  • VA Palo Alto Health Care System, Palo Alto, CA, USA; Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, USA.
  • VA Palo Alto Health Care System, Palo Alto, CA, USA; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.
  • Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, USA.
  • Institute for Advanced Diagnostics and Treatment, Sheppard Pratt Health System, Baltimore, MD, USA.
  • VA Palo Alto Health Care System, Palo Alto, CA, USA; Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, USA. Electronic address: tsuppes@stanford.edu.

Förderung

  • Compass Therapeutics LLC

Zitieren

APA

Ellis, S., Bostian, C., Feng, W., Fischer, E., Schwartz, G., Eisen, K., Lean, M., Conlan, E., Ostacher, M., Aaronson, S., & Suppes, T. (2025). Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression – A first-in-kind open-label pilot study. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2024.09.133

Vancouver

Ellis S, Bostian C, Feng W, Fischer E, Schwartz G, Eisen K, et al. Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression – A first-in-kind open-label pilot study. Journal of Affective Disorders. 2025. doi:10.1016/j.jad.2024.09.133

BibTeX
@article{Ellis2025,
  author = {Ellis, Sara and Bostian, Catherine and Feng, Wendy and Fischer, Eileen and Schwartz, Garrett and Eisen, Katherine and Lean, Melanie and Conlan, Elizabeth and Ostacher, Michael and Aaronson, Scott and Suppes, Trisha},
  title = {Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression – A first-in-kind open-label pilot study},
  journal = {Journal of Affective Disorders},
  year = {2025},
  doi = {10.1016/j.jad.2024.09.133}
}
Kostenlos starten →